Condition: Doxorubicin Induced Cardiomyopathy · Breast Cancer · Sponsor: Tanta University
This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.
This description comes directly from the study's public registry record.
Sandy Rezkallah, Bachelor · 01221065882 · sandyehab58@gmail.com
Osama M Ibrahim, Professor · osama.mohamed.ibrahim@pharm.tanta.edu.eg
Always discuss trial participation with your own doctor first.
| Medical Research Institute | Alexandria, Bab Sharqi, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06427226